Board of Directors approved the Company’s 2019 financial statement

  1. Date of occurrence of the event: Mar 13, 2020
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: Not applicable
  5. Cause of occurrence:
    The 2019 Individual/Consolidated Financial Statement, detailed as below:
    Individual Financial Statement:
    Operating loss:                                                  (1,321,659) thousand dollars
    Total comprehensive loss for the period:    (1,408,001) thousand dollars
    Loss Per Share (in dollars):                                      (7.76) dollars
    Consolidated Financial Statement:
    Operating loss:                                                 (1,450,861) thousand dollars
    Total comprehensive loss for the period:   (1,440,565) thousand dollars
    Loss Per Share (in dollars):                                     (7.76) dollars
  6. Countermeasures: Not applicable
  7. Any other matters that need to be specified: None